MBA

Advanced Glazings Ltd. Launches "Better Buildings for Humans" Podcast

Retrieved on: 
Monday, October 23, 2023
University of California, Berkeley, Science, CBE, Health, FRS, Oxford, AGL, Architecture, Glass, Solar, University, MBA, Research, Sunlight, Human, Better Buildings Act of 2014, Environment, Sleep, Marketing, School, Hospital, National University of Singapore, Only Human (podcast), Education minister, Built environment, Brasenose College, Oxford, Entertainment, Management, Ophthalmology

Sydney, Nova Scotia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Advanced Glazings Ltd. (“AGL”), creator of Solera® and Solera Wall®, and experts in state of the art glass solutions that greatly enhance the lives of building occupants, today announces the launch of the Better Buildings for Humans Podcast (“BBFH”). BBFH aims to revolutionize the discourse surrounding architectural innovation and is dedicated above all to exploring the profound impact of building design on human health, wellness, productivity, and lifestyle.

Key Points: 
  • “BBFH” is a new podcast exploring the vital relationship between buildings and human health, wellness, productivity and lifestyle, produced by Advanced Glazings Ltd., leaders in manufacturing and marketing sustainable and commercially viable technologies related to sunlight
    Sydney, Nova Scotia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Advanced Glazings Ltd .
  • (“AGL”), creator of Solera® and Solera Wall®, and experts in state of the art glass solutions that greatly enhance the lives of building occupants, today announces the launch of the Better Buildings for Humans Podcast (“BBFH”).
  • AGL has deep roots in architectural innovation, originating from the Advanced Glazing Lab and the Solar Thermal Lab at the University of Waterloo in 1996.
  • Stay tuned for riveting discussions, groundbreaking ideas, and unparalleled insights that will shape the future of architecture and building innovation.

Charles Griffie Appointed as Range Director

Retrieved on: 
Friday, October 20, 2023
Leadership development, Harvard Business School, LP, University of Colorado Denver Business School, NYSE, Midstream, ESG, NGL, MBA, Senior, RRC, Range, University, Anadarko Petroleum, Natural gas, Management, Engineering

FORT WORTH, Texas, Oct. 20, 2023 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced the appointment of Charles G. Griffie to its Board of Directors.

Key Points: 
  • FORT WORTH, Texas, Oct. 20, 2023 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced the appointment of Charles G. Griffie to its Board of Directors.
  • Range Chairman, Greg Maxwell, stated, “We are excited to announce the addition of Charles Griffie to the Range board as part of our ongoing refreshment process.
  • Mr. Griffie previously served as the Senior Vice President of Engineering and Operations at Western Midstream Partners, LP.
  • Prior to that, Mr. Griffie had an extensive career with Anadarko Petroleum Corporation where he worked in various roles of responsibility.

DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth

Retrieved on: 
Thursday, October 19, 2023
Distinction, Columbia Business School, Notre Dame, Assistant, Corporation, DMK, MBA, Wabash National, Supreme Industries, City, Yale University, Arcimoto, Purdue University, CT Corporation, Corporate lawyer, SAN, University, Tic disorder, CFO, Electronics, Lehman Brothers, General counsel, Dean Witter Reynolds Inc. v. Byrd, Management, Pension

SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced a series of management changes to optimize its leadership structure. Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary. Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio. These organizational changes will be effective immediately. The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline.

Key Points: 
  • Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary.
  • Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio.
  • The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline.
  • “We welcome Seth and John to our executive leadership team at a critical point for our company,” said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals.

Leslie’s, Inc. Appoints Seth Estep to Board of Directors

Retrieved on: 
Thursday, October 19, 2023
Martilla–Pettingel and Gorder General Merchandise Store, Tractor Supply Company, Belmont University, MBA, Leslie's, Senior, Growth, University, Safety, Management

"With Seth’s appointment we have expanded the breadth and depth of our Board of Directors.

Key Points: 
  • "With Seth’s appointment we have expanded the breadth and depth of our Board of Directors.
  • Mr. Estep said, “I am delighted to join the Leslie's board and collaborate with the management team as they fortify their leadership position in the pool and spa aftermarket industry.
  • Prior to his current role, Mr. Estep served as Senior Vice President, General Merchandising from 2017 to 2020.
  • Mr. Estep holds a bachelor’s degree from the University of Tennessee and an MBA in Finance from Belmont University.

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Retrieved on: 
Thursday, October 19, 2023
FDA, Trial of the century, IND, Food, MD, MBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, ATG, Clinical trial, U.S. FDA, Immunotherapy, Higgs phase, Safety, Patient, SAB, Investigational New Drug, Pharmaceutical industry, T1D

SIOUX FALLS, S.D., Oct. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it completed the approval process to commence a first-in-human Phase 1 clinical trial investigating SAB-142 in Australia.

Key Points: 
  • This first-in-human trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the SAB-142.
  • Approval by the HREC is confirmation that SAB has successfully completed all pre-clinical safety and efficacy testing required to commence a Phase 1 clinical trial.
  • More information about the Phase 1 clinical trial with SAB-142 (ACTRN:12623001089628) can be found here .
  • “We’d like to thank our clinical trial partners and express gratitude to everyone involved for their shared dedication to advancing innovative therapeutic options for those living with T1D.”

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

Retrieved on: 
Thursday, October 19, 2023
Neoplasm, Ayala, LLM, OTCQX, CPA, Plantar fibromatosis, Doctor of Philosophy, MBA, Master of Science, CFO, Chief medical informatics officer, FACP, Berlin, AML, Pharmaceutical industry, Management, MD

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.

Key Points: 
  • REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.
  • The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala’s current ticker symbol (“ADXS”).
  • “We are pleased to close the merger with Biosight which expands our product pipeline,” said Ken Berlin, President & CEO.
  • Roy Golan, CPA, LLM, previously Executive VP & CFO of Biosight, has been appointed Chief Financial Officer of the combined company.

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

Retrieved on: 
Thursday, October 19, 2023
CORAL, AstraZeneca, SVKM's NMIMS, TAP Pharmaceuticals, Rich, Catalyst (nonprofit organization), Notre Dame, Rare, Biotechnology, Takeda, Laboratory, Neuralstem, Inc., Diabetes, MBA, Catalyst Pharmaceuticals, Abbott Laboratories, Senior, Executive, University, Kellogg School, Metreleptin, Culture, Patient, Marketing, Bachelor of Science in Human Biology, Central nervous system, Management, Pharmaceutical industry, Science, Catalysis, Lipodystrophy

Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst.

Key Points: 
  • Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst.
  • "Today's announcement paves the way for a seamless transition for the new CEO at Catalyst.
  • "I am honored to serve as Catalyst's new CEO at such a pivotal point in the Company's evolution," said Richard J. Daly.
  • Prior to his appointment at Catalyst, Mr. Daly served as President of CARsgen Therapeutics Corporation since January 2022.

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

Retrieved on: 
Thursday, October 19, 2023
Pharmacology, CSO, University of Nottingham, Therapy, Bicycle, Rare disease, Swedish Orphan Biovitrum, Macrophage, GSK plc, University of Cambridge, MBA, Warwick Business School, Research, Inflammation, Disease, Drug discovery, GSK, University, Doctor of Philosophy, Parke Davis, University of Warwick, Pharmaceutical industry, Pfizer, MACOM Technology Solutions

EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director.

Key Points: 
  • EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director.
  • Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ: BCYC), Kevin brings two decades of biotech and pharma experience to Macomics.
  • He joined Bicycle from Pfizer, where he served as senior vice president and CSO of the Rare Disease Research Unit.
  • I look forward to work closely with Kevin to bring next generation macrophage targeting therapeutics to cancer patients.”

Sarcos Appoints Laura Peterson as President and Chief Executive Officer

Retrieved on: 
Wednesday, October 25, 2023
Data Management, Technology, Robotics, Security, Apps, Applications, Software, Artificial Intelligence, Networks, Internet, Mobile, Wireless, Hardware, GSAT, Boeing Commercial Airplanes, Stanford University, NYSE, Sprint, Business development, University, Sarcos, Clearwire, Vista Equity Partners, MBA, Globalstar, Engineering, Peterson, Wharton School of the University of Pennsylvania, ATSG, Executive, Boeing, BCA, Management

Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC and STRCW), a technology leader in advanced robotic systems, solutions, and software that redefine human possibilities, today announced that the Company’s interim President and Chief Executive Officer, Laura Peterson, has been appointed to serve as the Company’s permanent President and Chief Executive Officer.

Key Points: 
  • Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC and STRCW), a technology leader in advanced robotic systems, solutions, and software that redefine human possibilities, today announced that the Company’s interim President and Chief Executive Officer, Laura Peterson, has been appointed to serve as the Company’s permanent President and Chief Executive Officer.
  • The Company also announced that Sarcos co-founder, current director and former Chief Executive Officer, Ben Wolff, has re-joined the executive team as Executive Vice Chairman.
  • Peterson has served as interim President and Chief Executive Officer since May 2023 and has served on the Board of Directors since September 2021.
  • Wolff led the company from 2015 to 2021 as Chairman, President, and Chief Executive Officer and has served on the Company’s Board of Directors since 2015, including as Executive Chairman from December 2021 to January 2023.

Lara Balazs Joins Frontdoor Board of Directors

Retrieved on: 
Wednesday, October 25, 2023
Apps, Applications, Technology, Construction & Property, Women, Professional Services, Home Goods, Consumer, Retail, Residential Building & Real Estate, Other Professional Services, American Home Shield, Visa Inc., Amazon (company), Associated Students of the University of Washington, Visa, Nike (company), MBA, Social responsibility, Marketing, Executive, Gap Inc., University, Balázs, Management, Intuit, Northwestern University, FrontDoor

Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, today announced that its board unanimously approved the election of Lara Balazs as a director and appointed her as a member of the Nominating and Corporate Governance Committee, effective yesterday, October 24.

Key Points: 
  • Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, today announced that its board unanimously approved the election of Lara Balazs as a director and appointed her as a member of the Nominating and Corporate Governance Committee, effective yesterday, October 24.
  • “Lara has a deep understanding of consumers, digitally-focused businesses, and strategy that will make her a tremendous asset to our board,” said Bill Cobb, Frontdoor’s Chairman and Chief Executive Officer.
  • “I am thrilled to join the Frontdoor board,” Balazs said.
  • In addition to her, the Frontdoor board consists of the following directors: